CA2069439A1 - Monoclonal antibodies, their production and use - Google Patents

Monoclonal antibodies, their production and use

Info

Publication number
CA2069439A1
CA2069439A1 CA002069439A CA2069439A CA2069439A1 CA 2069439 A1 CA2069439 A1 CA 2069439A1 CA 002069439 A CA002069439 A CA 002069439A CA 2069439 A CA2069439 A CA 2069439A CA 2069439 A1 CA2069439 A1 CA 2069439A1
Authority
CA
Canada
Prior art keywords
antibody
prodrug
cancer
human
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002069439A
Other languages
English (en)
French (fr)
Inventor
Susumu Iwasa
Kayoko Okamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2069439A1 publication Critical patent/CA2069439A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002069439A 1989-12-15 1990-12-14 Monoclonal antibodies, their production and use Abandoned CA2069439A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP32654589 1989-12-15
JP1-326545 1989-12-15
JP9732390 1990-04-11
JP2-97323 1990-04-11
JP30160890 1990-11-06
JP2-301608 1990-11-06
PCT/JP1990/001631 WO1991009134A1 (en) 1989-12-15 1990-12-14 Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics

Publications (1)

Publication Number Publication Date
CA2069439A1 true CA2069439A1 (en) 1991-06-16

Family

ID=27308381

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002069439A Abandoned CA2069439A1 (en) 1989-12-15 1990-12-14 Monoclonal antibodies, their production and use

Country Status (3)

Country Link
EP (1) EP0505566A1 (de)
CA (1) CA2069439A1 (de)
WO (1) WO1991009134A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU665758B2 (en) * 1991-04-26 1996-01-18 Surface Active Limited Novel antibodies, and methods for their use
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
EP0611306B1 (de) * 1991-11-08 1998-07-08 Somatogen, Inc. Hämoglobine als arzneimittelabgabesystem
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
GB9819411D0 (en) * 1998-09-04 1998-10-28 Ks Biomedix Ltd Antibodies
AU763628B2 (en) * 1998-09-18 2003-07-31 Immunomedics Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US6573074B2 (en) 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
US8771679B2 (en) 2008-08-13 2014-07-08 The John Hopkins University Prodrug activation in cancer cells using molecular switches
AU2013302620B2 (en) * 2012-08-14 2018-08-02 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
JP6895890B2 (ja) 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
CN106554375B (zh) * 2016-06-08 2019-10-18 浙江海正药业股份有限公司 一种蒽环类化合物、其制备方法及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
EP0142905A2 (de) * 1983-03-30 1985-05-29 Bio-Response Inc. Therapeutisches Mittel für die Behandlung von Krankheiten wie Krebs
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems

Also Published As

Publication number Publication date
WO1991009134A1 (en) 1991-06-27
EP0505566A1 (de) 1992-09-30

Similar Documents

Publication Publication Date Title
US5141736A (en) Bispecific monoclonal antibody, its production and use
CA2069439A1 (en) Monoclonal antibodies, their production and use
US5028697A (en) Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5591593A (en) Minimum recognition unit of a PEM mucin tandem repeat specific monoclonal antibody and detection method using same
JP4255512B2 (ja) 多剤耐性表現型を標的とするための多重特異性免疫複合体と抗体組成物
AU597903B2 (en) Antibody complexes of hapten-modified diagnostic or therapeutic agents
EP0578774B1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
US4434156A (en) Monoclonal antibodies specific for the human transferrin receptor glycoprotein
EP0280209B1 (de) Monoklonale Antikörper gegen melanoma-assoziierte Antigene, Hybridzellinien, die diese Antikörper produzieren, und ihre Verwendung
US5217713A (en) Cytotoxic bispecific monoclonal antibody, its production and use
CN110240654A (zh) 结合cd73的抗体-药物偶联物
US20090280508A1 (en) Methods and Reagents for Preparing and Using Immunological Agents Specific for P-Glycoprotein
JPH03502885A (ja) 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CN114672490A (zh) 抗cd123抗体以及其缀合物和衍生物
EP1354896B1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
JP2002509158A (ja) アーム付きリガンドの送達向上のための抗体と受容体ターゲティング部分
US5144012A (en) Cytotoxic drug conjugates
US6051229A (en) Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions
AU2004289821B2 (en) Adenocarcinoma specific antibody SAM-6, and uses thereof
EP0336405B1 (de) Anti-Humankrebsproteinkomplexe, deren Herstellung und Verwendung
IWASA et al. Selective cytotoxicity of drug-monoclonal antibody conjugates against murine bladder tumor cells
CN115364238B (zh) 一种阿特珠单抗-mmad结合物及其制备方法与应用
WO2024012566A9 (en) Anti-trop2 antibody and conjugate thereof
JPH05506563A (ja) モノクローナル抗体、その製造法及び用途
AU611087B2 (en) Cytorhodin S derivatives, a process for their preparation and their use as medicaments

Legal Events

Date Code Title Description
FZDE Dead